1486 related articles for article (PubMed ID: 15203886)
1. Nicotinamide effects oxidative burst activity of neutrophils in patients with poorly controlled type 2 diabetes mellitus.
Osar Z; Samanci T; Demirel GY; Damci T; Ilkova H
Exp Diabesity Res; 2004; 5(2):155-62. PubMed ID: 15203886
[TBL] [Abstract][Full Text] [Related]
2. Intracytoplasmic cytokine levels and neutrophil functions in early clinical stage of type 1 diabetes.
Bilgic S; Aktas E; Salman F; Ersahin G; Erten G; Yilmaz MT; Deniz G
Diabetes Res Clin Pract; 2008 Jan; 79(1):31-6. PubMed ID: 17707941
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
4. Monitoring of polymorphonuclear leukocyte functions in diabetes mellitus--a comparative study of conventional radiometric function tests and low-light imaging systems.
Marhoffer W; Stein M; Schleinkofer L; Federlin K
J Biolumin Chemilumin; 1994; 9(3):165-70. PubMed ID: 7942121
[TBL] [Abstract][Full Text] [Related]
5. Sustained-release versus immediate-release glipizide for treatment of type 2 diabetes mellitus in chinese patients: A randomized, double-blind, double-dummy, parallel-group, 12-week clinical study.
Hsieh SH; Lin JD; Cheng HY; Ho C; Liou MJ
Clin Ther; 2006 Sep; 28(9):1318-26. PubMed ID: 17062305
[TBL] [Abstract][Full Text] [Related]
6. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
7. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
Habib SS; Aslam M; Naveed AK; Razi MS
Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671
[TBL] [Abstract][Full Text] [Related]
8. Oxidative DNA damage and plasma antioxidant capacity in type 2 diabetic patients with good and poor glycaemic control.
Lodovici M; Giovannelli L; Pitozzi V; Bigagli E; Bardini G; Rotella CM
Mutat Res; 2008 Feb; 638(1-2):98-102. PubMed ID: 17964614
[TBL] [Abstract][Full Text] [Related]
9. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
10. Plasma lipid peroxidation and antioxidiant nutrients in type 2 diabetic patients.
Peerapatdit T; Patchanans N; Likidlilid A; Poldee S; Sriratanasathavorn C
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S147-55. PubMed ID: 17718256
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
12. Advanced glycosylated end products-mediated activation of polymorphonuclear neutrophils in diabetes mellitus and associated oxidative stress.
Gupta A; Tripathi AK; Tripathi RL; Madhu SV; Banerjee BD
Indian J Biochem Biophys; 2007 Oct; 44(5):373-8. PubMed ID: 18341213
[TBL] [Abstract][Full Text] [Related]
13. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.
McCluskey D; Touger MS; Melis R; Schleusener DS; McCluskey D
Clin Ther; 2004 Nov; 26(11):1783-90. PubMed ID: 15639690
[TBL] [Abstract][Full Text] [Related]
14. Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction: a single-blind, 15-day clinical trial in patients with untreated type 2 diabetes, subjects with impaired glucose tolerance, and healthy controls.
Neri S; Signorelli SS; Torrisi B; Pulvirenti D; Mauceri B; Abate G; Ignaccolo L; Bordonaro F; Cilio D; Calvagno S; Leotta C
Clin Ther; 2005 Nov; 27(11):1764-73. PubMed ID: 16368447
[TBL] [Abstract][Full Text] [Related]
15. Impairment of the NO/cGMP pathway in the fasting and postprandial state in type 1 diabetes mellitus.
Farkas K; Jermendy G; Herold M; Ruzicska E; Sasvári M; Somogyi A
Exp Clin Endocrinol Diabetes; 2004 May; 112(5):258-63. PubMed ID: 15146372
[TBL] [Abstract][Full Text] [Related]
16. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
[TBL] [Abstract][Full Text] [Related]
17. In vitro reversal of hyperglycemia normalizes insulin action in fat cells from type 2 diabetes patients: is cellular insulin resistance caused by glucotoxicity in vivo?
Burén J; Lindmark S; Renström F; Eriksson JW
Metabolism; 2003 Feb; 52(2):239-45. PubMed ID: 12601640
[TBL] [Abstract][Full Text] [Related]
18. Polymorphonuclear cell-mediated phagocytosis and superoxide anion release in insulin-dependent diabetes mellitus.
Serlenga E; Garofalo AR; De Pergola G; Ventura MT; Tortorella C; Antonaci S
Cytobios; 1993; 74(298-299):189-95. PubMed ID: 8404029
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
20. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
